GlycoMimetics, Inc. (GLYC) News
Filter GLYC News Items
GLYC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest GLYC News From Around the Web
Below are the latest news stories about GLYCOMIMETICS INC that investors may wish to consider to help them evaluate GLYC as an investment opportunity.
GlycoMimetics: Q3 Earnings SnapshotROCKVILLE, Md. AP) — GlycoMimetics Inc. GLYC) on Wednesday reported a loss of $9.8 million in its third quarter. |
Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors, announced management will present at the Jefferies London Healthcare Conference on November 19, 2024, at 12:30 pm GMT/7:30 am EDT. |
GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual MeetingROCKVILLE, Md., November 06, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid leukemia (AML) have been accepted for presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Diego, California, on December 7-10, 2024. |
US Penny Stocks To Watch In October 2024As the U.S. stock market continues its upward trajectory with major indices like the Nasdaq hitting record highs, investors are keenly analyzing corporate earnings and economic data to gauge future opportunities. In this context, penny stocks—often representing smaller or newer companies—remain an intriguing area for those looking beyond established giants. Despite their name suggesting a bygone era, these stocks can offer significant potential when backed by strong financials and strategic... |
GlycoMimetics Announces Merger with Crescent BiopharmaGlycoMimetics ( (GLYC) ) has issued an update. GlycoMimetics, Inc. has announced a merger with Crescent Biopharma, aiming to enhance their presence in the biopharma sector. This merger, structured as a tax-free reorganization, will result in Crescent’s shareholders owning a significant majority of the combined entity. The transaction includes a substantial private placement of $200 million to support future growth and development. Both companies’ boards have approved the merger, expected to clos |
GlycoMimetics Enters Into Acquisition Agreement With Crescent BiopharmaROCKVILLE, Md., October 29, 2024--GlycoMimetics, Inc. (NASDAQ: GLYC) announced today it has entered into an acquisition agreement with Crescent Biopharma, Inc. ("Crescent"), a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. Upon completion of the transaction, the Company plans to operate under the name Crescent Biopharma, Inc. |
GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary EndpointROCKVILLE, Md., October 29, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the Phase 2 analysis of the adaptive Phase 2/3 study of uproleselan being conducted by the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology in adults with newly diagnosed acute myeloid leukemia (AML) who are 60 years or older and fit for inten |
GlycoMimetics Announces Strategic Review and Corporate Restructuring PlanROCKVILLE, Md., July 25, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the initiation of a strategic review and corporate restructuring plan. GlycoMimetics has engaged Lucid Capital Markets to act as a strategic advisor in the process. |
7 Sorry Biotech Stocks Set to Make Investors SadBiotech stocks are not for everyone, let’s make that perfectly clear. It’s challenging to invest in a field in which companies – particularly startups – can go for years without seeing a penny of revenue. While there are several outstanding companies from which to choose, the field is also littered with biotech stocks to sell before you get into too much trouble. Biotech stocks represent companies that are in the medical field. They develop and commercialize new medical treatments, drugs, and te |
Senior VP & Chief Medical Officer of GlycoMimetics Edwin Rock Buys 81% More SharesWhilst it may not be a huge deal, we thought it was good to see that the GlycoMimetics, Inc. ( NASDAQ:GLYC ) Senior VP... |